Share the post "Fredun Pharmaceuticals announced Financial Results Q1 2024-25"
Highlights
- The presented financial data is Standalone to provide a comprehensive overview of the company performance.
- Sales over the Year and quarter: The company experienced a substantial growth of 26.64 % in the past year, decrease in net sales/revenue by -33.85 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 55.68 %. Marginal increase in other income during this quarter, up by 55.68%.
- Profit over the Year and quarter: Significant improvement in profitability for Fredun Pharmaceuticals Limited. Notable increase of 71.94 % in net profit Year to Year, Fredun Pharmaceuticals Limited’s profitability dropped by -18.41 % Quarter to Quarter.
- EPS over the Year and quarter: EPS increased by 67.75 % Year to Year. EPS decreased by -18.38 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 61.227 Cr | Rs. 117.214 Cr | Rs. 77.536 Cr | -33.85 % | + 26.64 % |
| Expenses | Rs. 54.44 Cr | Rs. 106.87 Cr | Rs. 68.34 Cr | -36.05 % | + 25.53 % |
| Operating Profit | Rs. 6.79 Cr | Rs. 10.34 Cr | Rs. 9.2 Cr | -11.03 % | + 35.49 % |
| OPM % | 11.09 % | 8.82 % | 11.87 % | + 3.05 % | + 0.78 % |
| Other Income | Rs. 0.819 Cr | Rs. 0.819 Cr | Rs. 1.275 Cr | + 55.68 % | + 55.68 % |
| Interest | Rs. 2.61 Cr | Rs. 4.37 Cr | Rs. 3.91 Cr | -10.53 % | + 49.81 % |
| Depreciation | Rs. 0.92 Cr | Rs. 0.96 Cr | Rs. 1.05 Cr | + 9.38 % | + 14.13 % |
| Profit before tax | Rs. 4.08 Cr | Rs. 5.83 Cr | Rs. 5.52 Cr | -5.32 % | + 35.29 % |
| Tax % | 41.13 % | 13.29 % | 25.17 % | + 11.88 % | -15.96 % |
| Net Profit | Rs. 2.4 Cr | Rs. 5.06 Cr | Rs. 4.13 Cr | -18.38 % | + 72.08 % |
| EPS in Rs | Rs. 5.24 | Rs. 10.77 | Rs. 8.79 | -18.38 % | + 67.75 % |
Today, we’re looking at Fredun Pharmaceuticals Limited’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 26.64 %. However, it did see a marginal slip of -33.85 % from the previous quarter. Expenses decreased slightly by -36.05 % quarter-on-quarter, aligning with the annual rise of 25.53 %. Operating profit, while up 35.49 % compared to last year, faced a quarter-on-quarter dip of -11.03 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 0.78 %, but an expansion of 3.05 % sequentially. Other income rose by 55.68 % compared to the last quarter, despite an annual growth of 55.68 %. Interest expenses dropped significantly by -10.53 % from the previous quarter, yet the year-over-year increase remains at a moderate 49.81 %. Depreciation costs climbed by 9.38 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 14.13 %. Profit before tax grew annually by 35.29 % but saw a reduction from the preceding quarter by -5.32 %.
Tax expenses as a percentage of profits decreased slightly by -15.96 % compared to last year, with a more notable quarter-on-quarter increase of 11.88 %. Net profit rose by 72.08 % year-on-year but witnessed a -18.38 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 67.75 % but a quarterly fall of -18.38 %. In summary, Fredun Pharmaceuticals Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 61.227 Cr | Rs. 117.214 Cr | Rs. 77.536 Cr | -33.85 % | + 26.64 % |
| Expenses | Rs. 54.44 Cr | Rs. 106.87 Cr | Rs. 68.34 Cr | -36.05 % | + 25.53 % |
| Operating Profit | Rs. 6.79 Cr | Rs. 10.34 Cr | Rs. 9.2 Cr | -11.03 % | + 35.49 % |
| Net Profit | Rs. 2.4 Cr | Rs. 5.06 Cr | Rs. 4.13 Cr | -18.38 % | + 72.08 % |
| EPS in Rs | Rs. 5.24 | Rs. 10.77 | Rs. 8.79 | -18.38 % | + 67.75 % |
In reviewing Fredun Pharmaceuticals Limited’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 26.64 % year-on-year growth, although there was a slight dip of -33.85 % from the previous quarter. Expenses rose by 25.53 % compared to the previous year, with a decrease of -36.05 % quarter-on-quarter. Operating Profit surged by 35.49 % annually, and saw a -11.03 % decrease from the last quarter.
Net Profit showed yearly increase of 72.08 %, and experienced a -18.38 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 67.75 % annually, however dipped by -18.38 % compared to the last quarter. In essence, while Fredun Pharmaceuticals Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
[my_shortcode1 values=”Fredun Pharmaceuticals “]
